Correction to: Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells
verfasst von:
Neng Wang, Qi Wang, Hailin Tang, Fengxue Zhang, Yifeng Zheng, Shengqi Wang, Jin Zhang, Zhiyu Wang, Xiaoming Xie
Correction to: J Exp Clin Cancer Res 36, 172 (2017)
https://doi.org/10.1186/s13046-017-0635-9
Anzeige
Following publication of the original article [1], minor errors we identified in Fig. 6d and Fig. S4; specifically:
Figure 6d: incorrect image used for shCtrl scratch image (24 h); correct image now used
Fig. S4: incorrect images used for the invasive MDA-MB-231 cells (25 μM EA); correct images now used
Fig. 6
ACTN4 promotes breast cancer proliferation and metastasis in vitro and in vivo. a Intracellular expression of ACTN4 was determined by Western blot (left) and real-time PCR (right) analysis, respectively; b ACTN4 expression was modified by transfecting recombinant plasmid or its shRNA in breast cancer cells and subjected to Western blotting (left) and real-time PCR (right) validation; c MTT and colony formation assay showed that ACTN4 silencing abrogated breast cancer cell proliferation while its overexpression promoted cell growth; d ACTN4 silencing inhibited the migration and invasion abilities of MDA-MB-231 cells; e ACTN4 silencing inhibited breast cancer growth and lung metastasis in vivo (*P < 0.05, **P < 0.01 versus control, values represented as the mean ± SD, n = 3)
×
The corrected figures, produced using the original data, are given here. The correction does not have any effect on the final conclusions of the paper.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Correction to: Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells
verfasst von
Neng Wang Qi Wang Hailin Tang Fengxue Zhang Yifeng Zheng Shengqi Wang Jin Zhang Zhiyu Wang Xiaoming Xie
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.
Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.
Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
